SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

TSS, Inc. engages in the provision of comprehensive services for the planning, design, development and maintenance of mission-critical facilities and information infrastructure as well as integration services. It operates through the Facilities and Systems Integration Services business segments. The Facilities segment consists of the design, project management, and maintenance of data center and mission-critical business operations. The Systems Integration segment integrates information technology equipment for original equipment manufacturer vendors and customers to be used inside data center environments, including modular data centers. The company was founded by Gerard J. Gallagher on December 20, 2004 and is headquartered in Georgetown, TX.

TSS Inc

TSS Inc. is trending as investors digest a mix of financial results and potential tailwinds from the broader sector, with community discourse centered on the firm's strategic shift toward high-margin AI infrastructure and the implications of key talent acquisitions from Dell. While some market participants are reacting to headline revenue figures and insider selling, others see the current price action as an emotional dislocation that overlooks strong systems integration growth and the company's deepening integration within the AI data center supply chain.

The Mullen Army Token originated from a dedicated community of retail investors who faced challenges in the traditional stock market. We united to create a cryptocurrency that embodies our principles and aspirations for a fair financial system.     We provide a platform for retail investors to engage in a transparent and fair financial market. Our efforts include grassroots marketing, community engagement, and educational content to empower our investors.

MullenArmy

The MullenArmy is actively rallying behind the $MULN ticker on the Solana network, driven by community-led speculation of a potential weekend pump and nostalgia for past market cap highs. While supporters are encouraging others to "slap the ask" and fuel a bull run, critics are labeling the project a scam, pointing to the coin's association with a controversial CEO and warnings of repeated dilution patterns.

Polygon

Polygon is trending as investors monitor its strategic pivot toward institutional payments and real-world asset tokenization, fueled by excitement over potential regulatory clarity. The community remains deeply divided, with some bulls highlighting high network activity and deflationary upgrades as catalysts for a major rally, while frustrated long-term holders debate whether current price action reflects the network's underlying utility.

BLOCKLORDS

BLOCKLORDS is drawing significant community attention due to its extremely low circulating supply and small market cap, which many traders believe makes the token highly sensitive to sudden, explosive price moves. Investors are actively discussing its potential for volatility and are tracking its performance against other low-cap gaming tokens, debating whether the current interest is a sustainable breakout or just another cycle of rapid pumps and dumps.

Invesco Exchange-Traded Fund Trust II - Invesco Solar ETF

Invesco Solar ETF

Invesco Solar ETF (TAN) is attracting significant attention as investors weigh the impact of shifting political policies against the underlying necessity for robust energy infrastructure to support AI and data center expansion. The community is actively debating whether the current price levels represent a multi-year bottom and a strategic accumulation phase or a broader capitulation for the clean energy sector.

Exposure to multiple asset classes through a single yield bearing token

ASX Capital

Investors are navigating mixed sentiment and broader macroeconomic noise by focusing on selective, high-quality stock picking and defensive positioning. The community remains actively engaged in identifying resilient opportunities while monitoring momentum across sectors like tech and small caps.

Bitwise XRP ETF - Common Shares Of Beneficial Interest

Bitwise XRP ETF

XRP is trending as the market reacts to a surge in institutional inflows into recently launched spot ETFs, fueling community debate between those betting on long-term utility integration and those frustrated by current price consolidation. Investors are closely monitoring the impact of new institutional rails and regulatory developments while technical analysts highlight the tension between ongoing accumulation and persistent selling pressure.

Howard Hughes Holdings Inc. is a holding company. It operates through the following segments: Operating Assets, MPCs, Strategic Developments, and Seaport. The MPC segment is involved in the horizontal development of residential land and selling the improved acreage to homebuilders for the eventual sale of homes to new residents. The Strategic Developments segment focuses on building commercial properties at the appropriate time using the cash flow harvested from the sale of land to homebuilders which helps mitigate development risk. The Seaport segment includes a few multiblock districts largely under private management by a single owner and is being revitalized and enhanced into a mixed-use neighborhood featuring unique culinary and entertainment offerings. The company was founded on June 9, 2023 and is headquartered in The Woodlands, TX.

Howard Hughes Holdings Inc

Howard Hughes Holdings is drawing investor attention as it prepares to close its acquisition of Vantage Group Holdings, a move intended to diversify its earnings through insurance and long-term growth. The community remains focused on Bill Ackman's influence and strategic vision, debating whether the stock's current valuation effectively captures the company's underlying real estate assets and future potential.

Nextpower, Inc. engages in the provision of integrated solar tracker and software solutions used in utility-scale and ground-mounted distributed generation solar projects. Its products enable solar panels in utility-scale power plants to follow the sun's movement across the sky and optimize plant performance. The company was founded by Daniel S. Shugar, Alexander Au, Nicholas Miller, Michael Mehavich, Marco Garcia, and Tyroan Hardy in 2013 and is headquartered in Fremont, CA.

Nextpower Inc. - Ordinary Shares - Class A

Nextpower Inc.

Nextracker (NXT) is seeing heavy market interest following a strong quarterly earnings report that beat revenue expectations and resulted in a raised full-year earnings outlook. Community sentiment is largely bullish, with traders highlighting strong backlog growth and technical momentum, while institutional analysts have responded by aggressively hiking their price targets.

Got that dog in you? - Fueled by a mantra of tokenized self-belief, doginme is representative of the community's collective efforts to embrace and embolden that dog in them. doginme stands for knowing yourself and having that unshakable drive to keep pushing forward. doginme was originally launched in February 2024 when the Farcaster founder was asked if he owned a dog, to which he replied affirmatively: "no but I got that dog in me"

doginme

DOGINME is trending as investors rally around its "tokenized self-belief" narrative and strong community-driven culture on the Base chain. Enthusiasts are actively debating its potential for explosive growth, often highlighting its low market cap and comparing its community's resolve to early-stage meme coin runs.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

US tariffs on metals and pharma: Which Indian stocks are safe and which aren't: Sudip Bandyopadhyay

Indian equity markets face policy risks from US tariffs and West Asia conflict. These issues impact metals and pharmaceutical sectors. Expert Sudip Bandyopadhyay provides stock-specific insights. Vedanta and NALCO are well-positioned in aluminium. Tata Steel faces uncertainty due to European operations. Sun Pharma and Glenmark are at risk in the pharmaceutical sector due to branded drug exposure.

Indian Bank, Cummins, Glenmark Pharma: 3 stocks ideas for near-term gains, check targets

… suggested three stocks including Glenmark Pharmaceuticals Ltd, Cummins India and Indian … , supporting further upside potential. Glenmark Pharmaceuticals | Buy | Target Price: Rs 2 … Loss: Rs 1,988 Glenmark Pharma is displaying a constructive bullish setup …

Glenmark Pharmaceuticals Launches GLIPIQ® (Semaglutide) In India

… (Glenmark), a research-led, global pharmaceutical company, today announced the launch of … been approved by the Central Drugs Standard Control Organization (CDSCO) … Business Head, India Formulations, Glenmark Pharmaceuticals Ltd., said, "Affordability …

<ul class="summary-bullets"><li>Glenmark launched semaglutide under the brand name GLIPIQ for adults with Type 2 diabetes at ₹325 ($3.5) per week on Saturday.</li><li>The launch comes in a market where GLP-1 drugs such as Ozempic and Mounjaro are available at a much steeper cost.</li><li>The lower price point will reduce the cost barrier for diabetes and weight-loss treatment in India.</li></ul>As demand for diabetes and weight-loss treatments rises, Glenmark Pharmaceuticals Ltd (GLENMARK.NSE) has introduced a cost-effective version of semaglutide in India, aiming to improve affordability in a market dominated by higher-priced alternatives.Glenmark&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://glenmarkpharma.com/gpl_pdfs/media/PR_Glenmark%20Pharmaceuticals%20launches%20GLIPIQ%E2%93%87.pdf">launched</a> semaglutide under the brand name GLIPIQ for adults with Type 2 diabetes on Saturday, with weekly treatment costs starting at ₹325 ($3.5). The drug belongs to a class of medicines that help control blood sugar levels and are also used for weight management.The launch came in the market as GLP-1 drugs like Ozempic and Mounjaro are available at significantly higher prices. Weekly treatment using these can cost around ₹3,000 ($21) or more, depending on dosage and brand. At a more granular level, a 1 mg dose of Ozempic is priced near ₹12,000 ($128), while a 2.5 mg Mounjaro injection costs about ₹3,300 ($35).In comparison, GLIPIQ is priced between ₹325 and ₹440 ($3.5 to $4.7) per week, depending on dosage.Commenting on the launch, Alok Malik, President and Business Head, India Formulations at Glenmark Pharmaceuticals, said, “Affordability is one of the biggest barriers to initiating advanced diabetes treatment in India. With GLIPIQ, we are setting a new benchmark in affordability for GLP-1 drugs, with weekly treatment starting at ₹325.”<a href="https://stocktwits.com/symbol/GLENMARK.NSE/sentiment">GLENMARK.NSE</a> closed at ₹2,180 ($23.19) on Friday, trading up by almost 4%. On Stocktwits, the retail sentiment around GLENMARK.NSE improved from ‘neutral’ to ‘bullish,’ as chatter levels around it remained ‘normal’ over the past day.<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_03_21_at_2_24_01_PM_png_9e2a9418ca.webp" alt="Screenshot 2026-03-21 at 2.24.01 PM.png" width="1160" height="684"><figcaption>StocktwitsGLENMARK.NSE retail sentiment on March 21 as of 2:42 a.m. ET | Source: Stocktwits</figcaption></figure><h2 class="st-heading-2">Global GLP-1 Market</h2>The GLP-1 drug market has been dominated by Novo Nordisk (NVO) and Eli Lilly (LLY), whose products Ozempic and Monjaro are widely used for diabetes and weight management. However, patent expiries have reshaped the landscape.&nbsp;According to a Bloomberg&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2026-03-20/ozempic-copies-to-cost-14-in-india-as-generic-glp-1-era-starts">report</a>, Canada was among the first to lose patent protection for semaglutide earlier this year. The patent for semaglutide is also set to expire this month in China, Brazil, and Turkey. This positioned India as one of the first major markets to see the entry of lower-cost alternatives, as domestic drugmakers began launching competing products at a much lower cost.&nbsp;<h2 class="st-heading-2">How Is Stocktwits Reacting?</h2><stembedurl>https://www.stocktwits.com/TrendonomicsHD/message/648064809</stembedurl>One user on Stocktwits said that Glenmark is showing strong bullish technical signals despite a bearish sentiment. They pointed out that the stock appears to be in a "Stage 2 breakout," meaning it is starting to edge higher.Read also: <a href="https://stocktwits.com/news-articles/markets/cryptocurrency/bitcoin-whale-who-called-crash-warns--debt-hits-wwii/cZ3i55RRIiW">Whale Who Shorted Bitcoin In Black Swan Event Warns As US Debt Hits Highest Since World War II</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Ozempic is medicine for adults with type 2 diabetes that along with diet and exercise may improve blood sugar. While some doctors are prescribing it "off label" for weight loss, on March 17, 2026 in Sydney, Australia. (Photo by Steve Christo/Getty Images)

Glenmark Debuts Budget Semaglutide In India, Undercutting Ozempic By Over 80%

As the patents for semaglutide near expiry in several countries this month, India has introduced a cost-effective alternative.

Equity

As the patents for semaglutide near expiry in several countries this month, India has introduced a cost-effective alternative.


Rs 325–4,200/month: Dr Reddy’s, Sun Pharma, Glenmark kick off generic semaglutide price war

… Reddy’s Laboratories, Sun Pharma , Glenmark Pharmaceuticals , Alkem Laboratories, Zydus Lifesciences … , and Natco Pharma . Eris Lifesciences, which has a … first Indian pharma company to receive approval from the Drugs Controller General …

Sun Pharma, Dr Reddy's, Glenmark Launch Generic Semaglutide Injection in India

… markets." Another homegrown pharma major, Glenmark Pharmaceuticals Ltd also launched its …

Glenmark Pharmaceuticals Ltd. is a holding company, which engages in the development, manufacture, and marketing of pharmaceutical products. It operates through the following geographical segments: India, North America, Europe, Latin America, and Rest of the World. The company was founded by Gracias Saldanha on November 18, 1977 and is headquartered in Mumbai, India.

Current Price	2,368.00
Prev Close	2,370.00
Open	2,350.00
Dividend Yield	0.16%
50-Day Moving Average	2,209.03
Beta	0.03
Avg. Volume	659,905.71
PE Ratio	62.70

52-Week High	2,474.00
52-Week Low	1,355.40
Market Capitalization	667.22B
EPS (Annual)	37.11
Price to Book	6.97
Revenue Per Employee	8.01M

GLENMARK.NSE
Glenmark Pharmaceuticals Ltd.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest GLENMARK.NSE News

GLENMARK.NSEGlenmark Pharmaceuticals Ltd.